OptiBiotix Health PLC - York-based life sciences company - Reaches agreement with the University of Southampton and Italian academic research institute Fondazione Edmund Mach - Centro Ricerca e Innovazione. Under the agreement, they will jointly fund and carry out a research project examining the role of OptiBiotix's microbiome products in improving sleep, stress, and anxiety. The products include LPLDL, and SlimBiome/WellBiome. The deal includes a double blind placebo controlled human study to take place during a period of stress-induced sleep disruption.
Current stock price: 66.44 pence
Year-to-date change: up 15%
By Anna Farley; annafarley@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
OptiBiotix Health (OPTI)